Latest News

Arix Bioscience acquires 11% stake in Phamaxis Ltd.

Pharmaxis has two approved respiratory products: Bronchitol for cystic fibrosis and Aridol for the diagnosis and assessment of asthma.


by tg

An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.

London-based Arix Bioscience announced it has acquired an 11 % interest in Pharmaxis in a two tranche placement contributing £8m, while £5.4 came from existing investors such as BVF Partners L.P. The Pharmaxis Board approved the nomination of Arix’s Edward Rayner to join the Board in September 2018. 

Arix said it will use the proceeds to advance its proprietary Phase I lead programme, an orally administered anti-fibrotic Lysyl Oxidase-Like type 2 (LOXL2) inhibitor designed to block pathogenic fibrosis, which might create treatment options for diseases such as Non-alcoholic Steatohepatitis (NASH), Idiopathic Pulmonary Fibrosis (IPF), or heart and kidney fibrosis.  The company expects to finalise Phase I testing by Q3/2018. Furthermore, the company has two preclinical development programmes. In 2015, Pharmaxis' platform was validated through a licence deal with Boehringer Ingelheim – the candidate drug BI 1467335 (formerly known as  PXS-4728A) is in Phase II testing for NASH and Diabetic Retinopathy. 

AZ COPD drug fails in Phase III study

After the failure in the Phase III study enroling 1556 COPD patients, hopes of the British drugmaker are turning to a second ongoing Phase III study...

Researchers identify T cell guardians of the intestine

Intraepithelial lymphocytes (IELs), which protect the intestinal lining from pathogen invasion, remain in a semi-active state without release of...

CHMP greenlights first two CAR-T cell therapies in the EU

The first two CAR-T cell therapies and six orphan medicines are among the medicines the Committee recommended for EU market approval...

Small molecule restores liver regeneration

Paracetamol overdose is the most common cause of Acute Liver Failure, with around 200 UK and 2,000 US life threatening cases each year. Researchers...

Vifor Pharma in €70m pruritus drug deal

Under the terms of the agreement, Cara will receive an upfront payment of US$50m in cash and equity investment of US$20m to acquire Cara common...

Researchers remyelinate neurons

Peripheral nerves of patients with Charcot–Marie–Tooth disease 1A (CMT1A) display aberrant myelination during postnatal development, followed by...

Cell type switch helps colon cancer evade treatment

The pathologists headed by David Horst from LMU Munich found colorectal carcinomas to be composed of two different cell types that replace each other...